Trials / Completed
CompletedNCT00679601
Absorption and Systemic Study of AN2690 in Patients With Moderate to Severe Onychomycosis (ADME II)
An Open-label, Multiple-dose Study Of The Absorption And Systemic Pharmacokinetics Of An2690 Applied As A 7.5% Solution To All Toenails Of Adult Patients With Moderate To Severe Onychomycosis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to determine the absorption and systemic pharmacokinetics of AN2690 following daily application to all ten (10) toenails for 28 days.
Detailed description
A single center, open-label, multiple-dose study design will be used. Planned enrollment is 20 subjects to complete 15. Subjects must have a clinical diagnosis of onychomycosis of each great toenail and a clinical diagnosis of onychomycosis of six of the remaining toenails.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AN2690 | AN2690 7.5% Solution, once daily for 28 days |
Timeline
- Start date
- 2007-03-31
- Primary completion
- 2007-05-31
- Completion
- 2007-05-31
- First posted
- 2008-05-19
- Last updated
- 2018-02-20
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00679601. Inclusion in this directory is not an endorsement.